- Antibody is based in Motherwell, Scotland
- Antibody is NorthEdge’s sixth deal in the healthcare sector and its fourth in pharma services
- NorthEdge is a private equity firm
NorthEdge has completed its investment into Antibody Analytics, a contract research organisation (CRO) and immunology research service provider to an international client base.
Antibody is based in Motherwell, Scotland.
NorthEdge’s strategic investment in Antibody will enable job creation and expansion of its site, that will provide additional capacity and enable increased research capabilities, according to a release.
The investment was led by NorthEdge’s Jon Pickering, partner and CIO, Liam May, director and Simone Masterson, investment manager. May will join the board on behalf of NorthEdge.
“Antibody Analytics has a track record of developing strategically important services, alongside a pipeline of R&D projects that will further cement its reputation as a leader in its field,” said May. “The value creation plan leverages the company’s culture of innovation and blends it with a continued focus on quality, client service and a market-leading employee value proposition to facilitate scale.”
Antibody is NorthEdge’s sixth deal in the healthcare sector and its fourth in pharma services following investments into Helios, Meet and Ramarketing.
NorthEdge is a private equity firm with offices in Manchester, Leeds and Birmingham.
No financial details of the transaction were disclosed.
NorthEdge was advised by Hill Dickinson (legal), PMSI (commercial due diligence), RSM (financial and tax due diligence), Claritas (tax structuring) & Catalysis (organisational effectiveness). Antibody Analytics was advised by Baird (corporate finance) and Addleshaw Goddard (legal).
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
